Drug Profile
PBF 1650
Alternative Names: PBF-1650Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Palobiofarma
- Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Adenosine A1 receptor antagonists; Adenosine A3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Atopic dermatitis; Non-alcoholic steatohepatitis
- No development reported Psoriasis
- Discontinued Idiopathic thrombocytopenic purpura
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Psoriasis(In volunteers) in Spain (PO, Capsule)
- 17 Jul 2023 Phase-I clinical trials in Atopic dermatitis (PO) prior to July 2023 (Palobiofarma pipeline, July 2023)
- 12 Jan 2022 Development for Non-alcoholic steatohepatitis is underway in Spain (Palobiofarma pipeline, January 2022)